Investment
Features
FeesSafety
Academy
More
Pluang+

XAI Floating Rate Trust faces possible liquidation amid shareholder disputes over advisory plans.

Market News
30 Jul 2026
Seeking Alpha
View Source
Bearish
pluang ai news

The XAI Floating Rate & Alternative Income Trust (XFLT) is facing the possibility of liquidation at full net asset value if its board fails to secure 67% shareholder approval for a permanent sub-advisor plan. Currently, XFLT trades at about 80% of its net asset value, causing frustration among shareholders who feel the existing liquidity plan is inadequate. The board has already replaced Octagon with King Street as sub-advisor but can only retain King Street for 150 days without the required shareholder vote. Shareholders are pushing for more decisive actions, including potential fund liquidation, reverting to Octagon with a tender offer, or terminating the advisory agreement altogether.

More News

Telix Pharmaceuticals to release H1 2026 financial results on August 20 with investor webcast.

Telix Pharmaceuticals to release H1 2026 financial results on August 20 with investor webcast.

Telix Pharmaceuticals announced it will release its financial results for the half-year ended June 30, 2026, on August 20, 2026. An investor webcast and conference call will be held the same day to discuss the results. Telix is a global radiopharmace...

Company Fundamentals
Neutral
45 minutes ago
Inno Holdings stock to resume Nasdaq trading July 31, delayed to noon ET.

Inno Holdings stock to resume Nasdaq trading July 31, delayed to noon ET.

Inno Holdings Inc., a Texas-based electronic products trading company, announced that its common stock will resume trading on The Nasdaq Capital Market on July 31, 2026, around noon Eastern Time. This follows a trading halt imposed by Nasdaq under Co...

Market News
Neutral
52 minutes ago
FDA advisory panel finds Replimune's RP1 effective for advanced melanoma, supporting FDA review.

FDA advisory panel finds Replimune's RP1 effective for advanced melanoma, supporting FDA review.

The FDA's advisory committee voted 10 to 3 that the efficacy results from Replimune's IGNYTE study on RP1 combined with nivolumab for advanced melanoma are evaluable and clinically meaningful. This positive outcome supports the ongoing FDA review of ...

Market News
Bullish
1 hour ago
SAP Fioneer launches Cloud Accounting Subledger to simplify multi-GAAP accounting for financial firms.

SAP Fioneer launches Cloud Accounting Subledger to simplify multi-GAAP accounting for financial firms.

SAP Fioneer has introduced its Cloud Accounting Subledger, a cloud-based solution designed to help financial institutions manage complex multi-GAAP accounting requirements. The platform consolidates accounting standards like IFRS and US GAAP into a s...

Others
Bullish
1 hour ago
DBV Technologies raises $50M via At-The-Market ADS placement on Nasdaq to fund allergy treatment development.

DBV Technologies raises $50M via At-The-Market ADS placement on Nasdaq to fund allergy treatment development.

DBV Technologies announced a $50 million capital raise through the issuance of new American Depositary Shares (ADS) under its At-The-Market (ATM) program on Nasdaq. The placement involves issuing 3.66 million ADS, each representing five ordinary shar...

Company Fundamentals
Neutral
1 hour ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App